Skip to content
  • Sunday, 26 July 2026
  • 2:59 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
Pharmaceutical R&D

US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation

Teuku Ryan Apr 22, 2026 0

The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…

Read More
Clinical Diagnostics & Pathology

Keith J. Gray’s conviction underscores rising enforcement and audit risk as Medicare spending shifts toward high-cost genetic testing.

Reynand Amr Wu Apr 7, 2026 0

A federal jury in Dallas has delivered a resounding verdict, convicting Texas laboratory owner and former NFL player Keith J.…

Read More
Clinical Diagnostics & Pathology

Keith J. Gray’s conviction underscores rising enforcement and audit risk as Medicare spending shifts toward high-cost genetic testing.

Reynand Amr Wu Mar 30, 2026 0

A federal jury in Dallas has delivered a decisive verdict against Keith J. Gray, a 39-year-old Texas laboratory owner and…

Read More
Clinical Diagnostics & Pathology

Ex-NFL Player Convicted in $328M Genetic Testing Fraud as Medicare Scrutiny Intensifies

Reynand Amr Wu Mar 23, 2026 0

A federal jury in Dallas has delivered a resounding verdict against Keith J. Gray, a 39-year-old Texas laboratory owner and…

Read More
Science News: A Century of Empowering Public Understanding of Science5 Docker Best Practices for Faster Builds and Smaller ImagesScientists Replicate Human Bone Marrow Niches in Lab Setting to Revolutionize Blood Cancer Research and Reduce Animal TestingNovel Combination Therapy Offers Breakthrough Strategy for Overcoming Differentiation Blockade in Acute Myelogenous Leukemia
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ